Five loci, SLT1 to SLT5, controlling the susceptibility to spontaneously occurring lung cancer in mice

Cancer Research

Volumn 65, Issue 18, 2005, Pages 8158-8165

  Wang, Daolong ^a   You, Ming ^a  

^a MO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER SUSCEPTIBILITY; CHROMOSOME 19; CHROMOSOME 6; CHROMOSOME 7; CHROMOSOME 8; CHROMOSOME MAP; DATA BASE; GENE; GENE CONTROL; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; LUNG CANCER; LUNG CARCINOGENESIS; MOUSE; MOUSE STRAIN; NONHUMAN; NUCLEOTIDE SEQUENCE; POPULATION STRUCTURE; PRIORITY JOURNAL; QUANTITATIVE TRAIT LOCUS; SINGLE NUCLEOTIDE POLYMORPHISM; SLT1 GENE; SLT2 GENE; SLT3 GENE; SLT4 GENE; SLT5 GENE; X CHROMOSOME;

ANIMALS; BASE SEQUENCE; GENES, NEOPLASM; GENETIC PREDISPOSITION TO DISEASE; GENOME; GENOMICS; HAPLOTYPES; LINKAGE DISEQUILIBRIUM; LUNG NEOPLASMS; MICE; MICE, INBRED STRAINS; PHYSICAL CHROMOSOME MAPPING; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 24944537379     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-1508     Document Type: Article

References (42)

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin 2001;51:15-36.
2. Dragani TA. 10 years of mouse cancer modifier loci: human relevance. Cancer Res 2003;63:3011-8.
3. Demant P. Cancer susceptibility in the mouse: genetics, biology and implications for human cancer. Nat Rev Genet 2003;4:721-34.
4. Tripodis N, Hart AA, Fijneman RJ, Demant P. Complexity of lung cancer modifiers: mapping of thirty genes and twenty-five interactions in half of the mouse genome. J Natl Cancer Inst 2001;93:1484-91.
5. Pataer A, Nishimura M, Kamoto T, et al. Genetic resistance to urethan-induced pulmonary adenomas in SMXA recombinant inbred mouse strains. Cancer Res 1997;57:2904-8.
6. Ardlie KG, Kruglyak L, Seielstad M. Patterns of linkage disequilibrium in the human genome. Nat Rev Genet 2002;3:299-309.
7. Reich DE, Cargill M, Bolk S, et al. Linkage disequilibrium in the human genome. Nature 2001;411:199-204.
8. Malkinson AM. The genetic basis of susceptibility to lung tumors in mice. Toxicology 1989;54:241-71.
9. Drinkwater NR, Bennett LM. Genetic control of carcinogenesis in experimental animals. Prog Exp Tumor Res 1991;33:1-20.
10. Ihaka R, Gentleman R. R: a language for data analysis and graphics. J Comput Graph Statist 1996;5:299-314.
11. Churchill GA, Doerge RW. Empirical threshold values for quantitative trait mapping. Genetics 1994;138:963-71.
12. Lander E, Kruglyak L. Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results. Nat Genet 1995;11:241-7.
13. Devlin B, Roeder K. Genomic control for association studies. Biometrics 1999;55:997-1004.
14. Li JB, Gerdes JM, Haycraft CJ, et al. Comparative genomics identifies a flagellar and basal body proteome that includes the BBS5 human disease gene. Cell 2004;117:541-52.
15. Daigo Y, Takayama I, Ponder BA, et al. Novel human, mouse and xenopus genes encoding a member of the RAS superfamily of low-molecular-weight GTP-binding proteins and its down-regulation in W/WV mouse jejunum. J Gastroenterol Hepatol 2004;19:211-7.
16. Kremmidiotis G, Gardner AE, Settasatian C, et al. Molecular and functional analyses of the human and mouse genes encoding AFG3L1, a mitochondrial metalloprotease homologous to the human spastic paraplegia protein. Genomics 2001;76:58-65.
17. Ogryzko VV, Kotani T, Zhang X, et al. Histone-like TAFs within the PCAF histone acetylase complex. Cell 1998;94:35-44.
18. Hoyle J, Fisher EM. Genomic organization and mapping of the mouse P26s4 ATPase gene: a member of the remarkably conserved AAA gene family. Genomics 1996;31:115-8.
19. 2/prophase of the first meiotic cell cycle and in prevention of apoptosis. EMBO J 1997;16:5550-61.
20. Rudel T, Bokoch GM. Membrane and morphological changes in apoptotic cells regulated by caspase-mediated activation of PAK2. Science 1997;276:1571-4.
21. Li F, Adam L, Vadlamudi RK, et al. p21-activated kinase 1 interacts with and phosphorylates histone H3 in breast cancer cells. EMBO Rep 2002;3:767-73.
22. Denisenko ON, O'Neill B, Ostrowski J, Van Seuningen I, Bomsztyk K. Zik1, a transcriptional repressor that interacts with the heterogeneous nuclear ribonucleoprotein particle K protein. J Biol Chem 1996;271:27701-6.
23. Yoon SY, Lee Y, Kim JH, et al. Overexpression of human UHEB1 in colorectal cancer: HECT domain of human UREB1 inhibits the activity of tumor suppressor p53 protein. Biochem Biophys Res Commun 2005;326:7-17.
24. Gu J, Dubner R, Fornace AJ Jr, Iadarola MJ. UREB1, a tyrosine phosphorylated nuclear protein, inhibits p53 transactivation. Oncogene 1995;11:2175-8.
25. Tsuchiya E, Nakamura Y, Weng SY, et al. Allelotype of non-small cell lung carcinoma-comparison between loss of heterozygosity in squamous cell carcinoma and adenocarcinoma. Cancer Res 1992;52:2478-81.
26. Yoshioka H, Takeuchi T, Matsuno Y, et al. Analysis of loss of heterozygosity in small adenocarcinomas of the lung. Jpn J Clin Oncol 1998;28:240-4.
27. Dacic S, Sasatomi E, Swalsky PA, et al. Loss of heterozygosity patterns of sclerosing hemangioma of the lung and bronchioloalveolar carcinoma indicate a similar molecular pathogenesis. Arch Pathol Lab Med 2004;128:880-4.
28. Devereux TR, Holliday W, Anna C, et al. Map kinase activation correlates with K-ras mutation and loss of heterozygosity on chromosome 6 in alveolar bronchiolar carcinomas from B6C3F1 mice exposed to vanadium pentoxide for 2 years. Carcinogenesis 2002;23:1737-43.
29. Noll M, Battaile KP, Bateman R, et al. Fanconi anemia group A and C double-mutant mice: functional evidence for a multi-protein Fanconi anemia complex. Exp Hematol 2002;30:679-88.
30. Wong JC, Alon N, McKerlie C, et al. Targeted disruption of exons 1 to 6 of the Fanconi Anemia group A gene leads to growth retardation, strain-specific microphthalmia, meiotic defects and primordial germ cell hypoplasia. Hum Mol Genet 2003;12:2063-76.
31. Abounader R, Reznik T, Colantuoni C, et al. Regulation of c-Met-dependent gene expression by PTEN. Oncogene 2004;23:9173-82.
32. Steck PA, Pershouse MA, Jasser SA, et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 1997;15:356-62.
33. Gu J, Tamura M, Pankov R, et al. Shc and FAK differentially regulate cell motility and directionality modulated by PTEN. J Cell Biol 1999;146:389-403.
34. Jimenez AI, Fernandez P, Dominguez O, Dopazo A, Sanchez-Cespedes M. Growth and molecular profile of lung cancer cells expressing ectopic LKB1: downregulation of the phosphatidylinositol 3′-phosphate kinase/PTEN pathway. Cancer Res 2003;63:1382-8.
35. Bepler G, Sharma S, Cantor A, et al. RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer. J Clin Oncol 2004;22:1878-85.
36. Ferraro B, Bepler G, Sharma S, Cantor A, Haura EB. EGR1 predicts PTEN and survival in patients with non-small-cell lung cancer. J Clin Oncol 2005;23:1921-6.
37. Gautam A, Li ZR, Bepler G. RRM1-induced metastasis suppression through PTEN-regulated pathways. Oncogene 2003;22:2135-42.
38. Krammer PH, Behrmann I, Daniel P, Dhein J, Debatin KM. Regulation of apoptosis in the immune system. Curr Opin Immunol 1994;6:279-89.
39. Sibley K, Rollinson S, Allan JM, et al. Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res 2003;63:4327-30.
40. Chang JS, Hsu YL, Kuo PL, Chiang LC, Lin CC. Upregulation of Fas/Fas ligand-mediated apoptosis by gossypol in an immortalized human alveolar lung cancer cell line. Clin Exp Pharmacol Physiol 2004;31:716-22.
41. De Paepe ME, Mao Q, Embree-Ku M, Rubin LP, Luks FI. Fas/FasL-mediated apoptosis in perinatal murine lungs. Am J Physiol Lung Cell Mol Physiol 2004;287: L730-42.
42. Dahlen A, Debiec-Rychter M, Pedeutour F, et al. Clustering of deletions on chromosome 13 in benign and low-malignant lipomatous tumors. Int J Cancer 2003;103:616-23.